Prostate cancer (PCa) is the most commonly diagnosed, non-cutaneous male cancer and is the third leading cause of cancer-related death in North America ([@bib15]). The ability to predict, *a priori*, an individual PCa patient\'s tumour response to surgery, image-guided radiotherapy (IGRT), external beam radiotherapy (EBRT), androgen deprivation (AD) or taxane-based chemotherapy is based on pretreatment clinical factors, including the absolute value and doubling time of prostate-specific antigen (PSA), tumour stage (TNM staging), pathologic Gleason score (GS) and performance status ([@bib22]; [@bib30]; [@bib3]). Prostate-specific antigen is a kallikrein protease produced almost exclusively by luminal cells in the prostate gland ([@bib30]) and its tissue specificity is an important property as a serum biomarker. In large cohorts, the pre- and posttreatment absolute value, and doubling time of PSA, may predict disease-free survival (DFS) and long-term response to localised and systemic treatment ([@bib10]; [@bib30]). Using PSA alone to monitor EBRT response can be problematic due to the long time (12--24 months) to reach a PSA-nadir, the difficulty in using PSA to monitor tumour cell kill during AD and PSA 'bounces\' and changes due to benign causes ([@bib10]). Nonetheless, PSA remains the exclusive blood biomarker used to place patients into prognostic risk groups to determine overall tumour burden and track response following local or systemic treatment ([@bib10]).

Additional biomarkers that could be used with PSA to denote non-aggressive from aggressive disease, including increasing tumour bulk and/or the presence of occult metastases in the D\'Amico high-risk group (any one of: PSA\>20 ng ml^−1^, T3/T4N0M0, GS 8 or above), could effectively triage patients to more individualised PCa management ([@bib10]; [@bib7]). There has been substantial interest in osteopontin (OPN) as a biomarker of cancer aggression, tumour hypoxia and response to treatment ([@bib24]; [@bib23]; [@bib5]; [@bib29]; [@bib1]). Osteopontin is a small integrin-binding ligand *N*-linked glycoprotein (SIBLING) that binds to cell surface receptors including integrins and CD44. It is expressed in many tissues and secreted into body fluids, including blood, milk and urine. Osteopontin has important physiological roles in bone remodeling, immune response and inflammation. It is also a tumour-associated protein and elevated OPN levels are associated with cellular proliferation, invasion and angiogenesis via altered activity of matrix metalloproteinases, the epidermal growth factor receptor and PI3K-AKT signaling ([@bib8]; [@bib1]). These preclinical studies suggest that plasma OPN could be an important biomarker of occult systemic metastases.

In a recent meta-analysis of over 228 publications, high plasma or tissue OPN levels correlated with decreased overall survival and DFS across a number of different tumour types, including lung cancer, breast cancer, head and neck cancer, liver cancer and PCa ([@bib29]). High tumour OPN levels as determined by immunohistochemistry (IHC) *in situ* are associated with pretreatment tumour hypoxia and are prognostic following PCa EBRT ([@bib27]). In the DAHANCA-5 head and neck trial, high plasma OPN concentrations were correlated with tumour hypoxia and predicted poor loco-regional control following EBRT ([@bib23]). Hypoxia in PCa has an important role as it correlates with increased clinical stage and poor prognosis following EBRT and surgery ([@bib21]; [@bib9]; [@bib27]; [@bib20]).

To date, a definitive study of plasma OPN as a biomarker of increasing tumour aggression (bulk/stage, grade, PSA) across both localised and systemic disease has not been published. Given the reported aggressive nature of OPN-expressing tumours, we explored the role of circulating OPN expression as a potential surrogate biomarker of PCa tumour aggression and occult metastasis. We also assessed OPN levels in response to treatment in both localised and systemic disease.

Materials and methods
=====================

Patient samples
---------------

Plasma samples were prospectively collected from consenting patients with newly diagnosed PCa attending clinics at Princess Margaret Hospital (University Health Network; University of Toronto) or the London Regional Cancer Center (University of Western Ontario). Written informed consent for blood collection for research purposes was obtained from all patients on local Research Ethics Board (REB)-approved studies of proteomics and biobanking in genitourinary cancers (GU BioBank) (PMH-UHN REB 10-0223-T/08-0124-T). Additional plasma samples in patients with biopsy-proven locally recurrent PCa following treatment with radiotherapy were collected as part of a PHASE I study of MRI-guided prostate biopsies (PMH-UHN REB 05-0641-C). Specimens were collected from 208 men with localised PCa (54, 84, and 61 with low, intermediate and high risk, respectively, and 9 patients with biopsy-proven local recurrence (LR) following radiotherapy ) and 37 men with CRPC-MET. Risk categories were defined by the D\'Amico criteria ([@bib12]; [@bib22]) defined as: (1) low risk defined as clinical stage T1 to T2aN0M0, GS 4--6 and PSA of \<10 ng ml^−1^; (2) intermediate risk defined as clinical stage T1 to T2N0M0 and GS of 7 or PSA of 10--20 ng ml^−1^; (3) high risk defined as clinical stage T3-T4N0M0 or GS of 8--10 or PSA\>20 ng ml^−1^.

Patients with localised low-risk disease were treated with radical prostatectomy (28) or active surveillance (26). Intermediate-risk patients were treated with radical prostatectomy (22) with lymph node sampling or lymphadenectomy (with or without nerve sparing) or intensity-modulated radiotherapy with image guidance (IGRT-IMRT; 60 Gy in 20 fractions or 78 Gy in 39 fractions) (62) ([@bib28]). Fifteen localised high-risk patients were treated with pelvic and prostatic IMRT radiotherapy (pelvic dose of 46 Gy and total prostate dose 74 Gy) plus AD therapy (e.g., LHRH-agonist injections given as concurrent and adjuvant therapy for a total period of 3 years) and 45 high-risk patients underwent radical prostatectomy with lymph node sampling or lymphadenectomy. Thirty seven CRPC-MET patients were treated with docetaxel chemotherapy at 75 mg m^−2^ every 3 weeks with prednisone ([@bib26]) ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). Control plasma OPN samples were collected from 26 healthy volunteers. We also assessed plasma OPN levels from 96 men presenting negative biopsies who were at higher risk for developing PCa (PMH-UHN REB 09-0787-T).

Plasma OPN levels and PSA at baseline were determined for each group of patients before treatment. In a subgroup of patients, OPN and PSA were compared pre- and posttreatment. We defined response to chemotherapy as a \>50% reduction in PSA following docetaxel chemotherapy. Blood samples were obtained from patients at the pretreatment appointment and at 1 year posttreatment. For CRPC-MET patients, blood samples were collected before and after the second, third or fourth cycles. Patient-derived toxicity grading was prospectively collected using the Common Terminology Criteria for Adverse Events v3.0 (CTCAE v3.0) as previously described ([@bib11]). Patients were asked to complete questionnaires concerning symptoms of rectal or bladder injury before, and every week during, radiotherapy as part of their standard of care.

Enzyme-linked immunosorbent assay (ELISA) for OPN
-------------------------------------------------

Reporting of plasma OPN measurements and analysis was completed using the National Cancer Institute and European Organization for Research and Treatment of Cancer recommendations for reporting tumour marker prognostic studies ([@bib19]). The dual monoclonal human OPN ELISA kit (Catalog 900-142, Enzo Life Sciences, Plymouth Meeting, PA, USA), was used as previously published ([@bib2]) using the manufacturer\'s instructions. Human recombinant OPN provided with this kit was used as a standard. Duplicate readings of each plasma sample were averaged.

Statistical analyses
--------------------

Non-parametric tests were applied to investigate the differences in OPN values between the different risk groups (Mann--Whitney test) or between the pre- *vs* posttreatment (Wilcoxon-signed rank test). Spearman\'s correlation coefficients were calculated to assess correlations between OPN and PSA.

To evaluate the performance of OPN values as a predictor for metastatic disease we plotted the receiver-operating characteristic (ROC) curve. As a measure of performance we calculated the area under the ROC (AUC). The software programs utilized were SAS/STAT Version 9.2 (SAS Institute Inc., Cary, NC, USA) and R ([@bib14]). For all analyses, *P*⩽0.05 was interpreted as significant.

Results
=======

[Table 1](#tbl1){ref-type="table"} shows the baseline characteristics of all the patients in the study. We initially tested differences in OPN and PSA between cohorts of patients with low-risk, intermediate-risk, high-risk prostate and CRPC-MET cancers. In pair-wise testing, PSA differentiated between all tested groups (see [Supplementary Table 2](#sup1){ref-type="supplementary-material"}). We then compared OPN values in the same groups of patients and found that OPN values were not statistically significantly different between low-, intermediate- or high-risk groups ([Figure 1A](#fig1){ref-type="fig"}, and [Supplementary Table 2](#sup1){ref-type="supplementary-material"}). The OPN values of the CRPC-MET group of patients in this study were similar to a previous published cohort of CRPC-MET using a similar ELISA (20). In each of the localised disease-risk groups, we observed heterogeneity in OPN with values ranging from 12 to 438 ng ml^−1^ (see [Supplementary Table 3a](#sup1){ref-type="supplementary-material"}). The OPN levels in the CRPC-MET group (range: 56--513 ng ml^−1^) were significantly higher to values measured in the localised risk groups (overall mean values of 72 *vs* 219 ng ml^−1^; *P*\<0.0001; see 1 : 1 comparisons in [Supplementary Table 2](#sup1){ref-type="supplementary-material"}). To assess the performance of plasma OPN in distinguishing men with high-risk cancer *vs* intermediate and low-risk cancer ([Figure 1B](#fig1){ref-type="fig"}) or localised *vs* CRPC-MET disease ([Figure 1C](#fig1){ref-type="fig"}), ROC analyses were performed. [Figure 1B](#fig1){ref-type="fig"} shows that the AUC was 0.505 (95% confidence interval (CI) 0.417--0.542) for OPN alone. For PSA the AUC was 0.717 (95% CI; 0.632--0.803) and for PSA and OPN together the AUC was 0.72 (95% CI; 0.635--0.806). [Figure 1C](#fig1){ref-type="fig"} shows that the AUC for distinguishing CRPC-MET was 0.935 (95% CI; 0.889--0.982) for OPN alone. For PSA the AUC was 0.943 (95% CI; 0.872--1.0) and for PSA and OPN together the AUC was 0.969 (95% CI; 0.918--1.0).

Taken together, these data confirm that higher circulating plasma OPN levels are observed in CRPC-MET patients as compared with other groups; plasma OPN does not differentiate high-risk patients when compared with intermediate-risk and low-risk patients; plasma OPN is as good as PSA as a predictor of CRPC-MET.

Plasma OPN could be an important biomarker of local or systemic recurrence following surgery or EBRT. However, plasma OPN levels were not uniquely elevated in biopsy-proven LRs following EBRT when compared with localised PCas or non-cancer normal volunteers (*P*\>0.05; [Figure 1A](#fig1){ref-type="fig"}). We also noted high plasma levels outliers in [Figure 1A](#fig1){ref-type="fig"} (defined as OPN\>100 ng ml^−1^ for non-CRPC-MET patients and OPN\>400 ng ml^−1^ for CRPC-MET patients). A careful chart review did not show that these patients have different clinical outcomes as compared with individuals from the same risk category. This could also represent inflammation-related comorbidities (e.g., rheumatoid arthritis) (24); however, we did not find an association to known comorbidities or clinical symptoms at the time of assay.

Given its role in cell proliferation, hypoxia, angiogenesis and metastasis, OPN could also be an important biomarker for treatment response if it reflected overall local and/or tumour bulk similar to PSA. We therefore investigated whether there was any evidence for change in OPN levels in localised PCas treated with surgery or EBRT ([Figure 2](#fig2){ref-type="fig"}). In the low-risk patients that were treated by surgery ([Figure 2A](#fig2){ref-type="fig"}), 13 out of 18 patients showed decreased OPN values following surgery with the removal of the entire prostate gland. One out of the five patients without decreasing OPN postsurgery had detectable PSA. The mean change in OPN was −26.5 ng ml^−1^. A significant decrease in OPN was not observed in high- and intermediate-risk patients after surgery ([Figures 2B and C](#fig2){ref-type="fig"}, respectively). There was great heterogeneity in the response of intermediate-risk patients to EBRT with the prostate gland remaining *in situ* as the overall mean change of OPN in this group was −0.9 ng ml^−1^ ([Figures 2D and E](#fig2){ref-type="fig"} and Figure 4). We also hypothesised that OPN response may differ based on EBRT fraction size or duration and we therefore compared the response in patients receiving 60 Gy in 20 daily fractions (3 Gy fractions; 4 weeks) *vs* 78 Gy in 39 daily fractions (2 Gy fractions; 8 weeks) using EBRT. We did not find any significant OPN change related to altered fraction size or duration during or after EBRT ([Figures 2D and E](#fig2){ref-type="fig"} and [Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). We also found no evidence for increased baseline or intra-treatment OPN values in patients that had increased acute toxicity (i.e., maximum CTCAE scores 2 out of 3 *vs* 0 out of 1) during EBRT (see [Supplementary Table 4](#sup1){ref-type="supplementary-material"}).

We next investigated whether OPN levels were altered in response to systemic therapies. In the high-risk patients treated with radiotherapy plus AD therapy, the mean OPN level significantly surprisingly increased (+12.4 ng ml^−1^) even though all patients had PSA response at this time point with no evidence of castrate resistance ([Figure 3A](#fig3){ref-type="fig"}). In patients with CRPC-MET receiving two to four cycles of docetaxel chemotherapy there was a statistically significant decrease in OPN levels (−29.1 ng ml^−1^, *P*-value=0.027; see [Figure 3B](#fig3){ref-type="fig"}). In five patients, there was no reduction in both PSA and OPN with chemotherapy. Fifteen patients had both OPN and PSA decrease after treatment. In all of the responding patients, five patients had an increase in plasma OPN and the remaining seven patients showed minimal change in OPN. The PSA and OPN differences by chemotherapy cycle are presented in [Supplementary Figure 2](#sup1){ref-type="supplementary-material"}.

Finally, we correlated OPN to PSA in our patient cohorts. The change in OPN and PSA following treatment for each patient was calculated and shown in [Figure 4](#fig4){ref-type="fig"}. For patients receiving local therapy or systemic therapies, we observed expected reductions in PSA values, but a heterogeneous response with respect to OPN values. The change in OPN does not track with the change of PSA in patients receiving EBRT. Finally, we tested whether plasma OPN levels were a surrogate for serum PSA at baseline or following treatment ([Supplementary Figure 3a--c](#sup1){ref-type="supplementary-material"}). Plasma PSA and plasma OPN are not correlated at baseline (in all patients or even in the subgroup analysis of localised PCas; Spearman\'s correlation coefficients of 0.226 and −0.05, respectively), nor at 1 year posttreatment (Spearman\'s correlation coefficient=0.366). We conclude that plasma OPN expression is not a surrogate for serum PSA.

Discussion
==========

Unlike the suggested role of OPN in treatment response in head and neck, lung and breast cancers ([@bib23]; [@bib6]; [@bib17]; [@bib5]), our novel report suggests that plasma OPN in localised PCa is not predictive of response to local therapy when compared with changes in PSA following therapy. In particular, we found no evidence of significantly elevated baseline levels of OPN in high-risk but localised disease relative to low- and intermediate-risk disease. Hence, unlike PSA, OPN is not a direct marker of tumour burden. Longer follow-up will be needed to absolutely determine whether the high OPN outliers in localised risk groups will ultimately fail but we had no evidence that ultra-high levels (\>100 ng ml^−1^) of OPN in localised disease at diagnosis heralds a more aggressive cancer after treatment.

[@bib27] suggested that IHC staining for tumour OPN *in situ* was prognostic for response following EBRT or surgery. We did not examine OPN-IHC expression in PCa biopsies in this study. But given the lack of an observed difference between baseline expression of plasma OPN in patients with high-risk PCa and normal volunteers, we would not expect a high degree of concordance between plasma OPN and OPN-IHC as positive staining of OPN *in situ* occurs in 25% percent of localised PCas ([@bib27]). [@bib18] recently reported on a number of SIBLING proteins, including plasma OPN, in men with PCa treated with radical prostatectomy. Our results are consistent with their findings, as they did not observe a significant difference in plasma OPN expression between subgroups of patients with different GSs. However, their study did not categorise the patients according to risk group nor treatment response. We observed a significant correlation of plasma OPN to PSA levels pre- and posttreatment following surgery or chemotherapy, but not following radiotherapy or AD, despite strong PSA decline. Plasma OPN levels are therefore not likely to directly reflect PCa cell death during radiotherapy or AD when the prostate gland remains *in situ*. Further preclinical work using PCa models will be needed to understand this observation. It will also be important to study OPN following second-generation AD therapies such as abiraterone or MDV3100 ([@bib13]; [@bib25]).

We have previously reported using the same plasma samples from the EBRT cohort that there was a significant increase in IFN-gamma and IL-6 during EBRT. In this study, increasing IL-2 and IL-1 expression were associated with increased probability of acute gastrointestinal and genitourinary toxicity, respectively ([@bib11]). As OPN is secreted by activated macrophages, leukocytes and activated T lymphocytes and is chemotactic for macrophages and neutrophils, we hypothesised that OPN could have a role in EBRT-associated toxicity and acute inflammatory response ([@bib24]; [@bib8]; [@bib4]; [@bib29]). However, our data do not support plasma OPN as a biomarker of endogenous or iatrogenic (e.g., EBRT-induced) inflammation (See [Supplementary Figure 1](#sup1){ref-type="supplementary-material"} and [Supplementary Table 4](#sup1){ref-type="supplementary-material"}). We speculate that the overall driving mechanism of increased baseline plasma OPN levels in our CRPC-MET patients is secondary to OPN\'s roles in tumour cell adhesion, migration and matrix degradation during the formation of bone metastases ([@bib16]; [@bib24]; [@bib29]). It would be of interest to measure OPN response to intermittent AD during the intervals 'on\' and 'off\' therapy in prostate patients with biochemical recurrent disease. In the setting of CRPC-MET and docetaxel chemotherapy treatment, reduced OPN levels was observed in 23 of 31 patients. Reductions in plasma OPN in CRPC-MET patients may therefore be biomarker of response relating to bone metastases.

Conclusion
==========

Plasma OPN is a biomarker of CRPC-MET. Plasma OPN might be used to track response to chemotherapy, where it correlates to treatment-induced changes in PSA. However, OPN levels do not directly track PSA changes following EBRT or AD and may not reflect local or occult metastatic burden in PCa. Our studies support future prospective studies of the use of plasma OPN as a response biomarker in PCa chemotherapy trials.
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![Elevated plasma OPN is associated with CRPC-MET patients. (**A**) Baseline plasma OPN expression per risk category and in normal volunteers. Plasma OPN values were measured by ELISA assay in localised PCa patients (low, intermediate, high-risk and LR-locally recurrent cancer following radiotherapy); CRPC-MET -- castrate-resistant metastatic PCa and non-cancer normal volunteers. (The mean value of plasma OPN values in CRPC-MET as previously published by Anborgh *et al* (2009) is shown by the black bar (219 *μ*g ml^−1^)). CRPC-MET patients had significantly increased OPN values compared with localised PCas, including high-risk patients (*P*-value 0.0001). (**B**) Receiver-operating curves (ROC) analysis for high-risk patients *vs* low- and intermediate-risk patients. For OPN: AUC=0.505; 95% CI=0.417--0.542; PSA: AUC=0.717, 95% CI=0.632--0.803; OPN+PSA: AUC=0.72, 95% CI=0.635--0.806. (**C**) Receiver-operating curves analysis for localised *vs* castrate resistance PCa patients with known metastatic disease. For OPN: AUC=0.935; 95% CI=0.889--0.982; PSA: AUC=0.943, 95% CI=0.872--1.0; OPN+PSA: AUC=0.969, 95% CI=0.918--1.0.](bjc2012345f1){#fig1}

![Plasma OPN expression in response to local treatment. For each figure: black lines represents patients with decreasing plasma OPN from baseline following treatment, whereas red lines represents patients with increasing plasma OPN from baseline following treatment. The median values pre and post treatment are indicted by the horizontal black bar. (**A**) Low-risk PCa treated with radical prostatectomy (*n*=18); (**B**) High-risk PCa treated with radical prostatectomy and pelvic lymph node dissection (*n*=39); (**C**) Intermediate risk PCa treated with radical prostatectomy±pelvic lymph node dissection (*n*=22); (**D**) Intermediate-risk PCa treated with IMRT 60 Gy in 20 daily fractions (*n*=12); (**E**) Intermediate-risk PCa treated with IMRT 78 Gy in 39 daily fractions (*n*=29); Only in the low risk group there was a significant response in OPN following surgery (*P*-value 0.005).](bjc2012345f2){#fig2}

![Plasma OPN expression response to systemic therapies. For each figure: black lines represents patients with decreasing plasma OPN from baseline following treatment, whereas red lines represents patients with increasing plasma OPN from baseline following treatment. The median values pre and post treatment are indicted by the horizontal black bar. (**A**) High-risk PCa treated with combined modality therapy of IMRT 74 Gy in 37 daily fractions and AD therapy (ADT) for 3 years (At 1 year post IMRT all patients were continuing on ADT). (**B**) Metastatic castrate-resistant PCa treated with two to four cycles of chemotherapy.](bjc2012345f3){#fig3}

![Change in OPN and PSA at 1 year post treatment from baseline before therapy. The change in OPN from baseline following treatment in each of the risk groups (upper bar plots) is heterogeneous compared with the reduction in PSA following (lower bar plots) for both local and systemic therapies.](bjc2012345f4){#fig4}

###### Patients\' characteristics

                 **Controls (26)**   **Biopsy negative (96)**   **Low (*****N*****=54)**   **Int (*****N*****=84)**   **High (*****N*****=61)**   **LR (*****N*****=9)**   **CRPC-MET (*****N*****=37)**   **Overall (*****N*****=367)**
  -------------- ------------------- -------------------------- -------------------------- -------------------------- --------------------------- ------------------------ ------------------------------- -------------------------------
  Age (median)   30                  61                         62                         64                         63                          70                       72                              63
                                                                                                                                                                                                            
  *PSA*                                                                                                                                                                                                    
   \<10          ---                 86                         53                         68                         31                          9                        2                               249
   10--20        ---                 10                         1                          16                         18                          ---                      ---                             45
   \>20          ---                 0                          ---                        ---                        12                          ---                      35                              47
                                                                                                                                                                                                            
  *Gleason*                                                                                                                                                                                                
   6             ---                 ---                        54                         8                          ---                         ---                      ---                             63
   7             ---                 ---                        ---                        76                         27                          6                        14                              123
   8--10         ---                 ---                        ---                        ---                        34                          ---                      20                              54
   Unknown       ---                 ---                        ---                        ---                        ---                         3                        3                               6
                                                                                                                                                                                                            
  *T-category*                                                                                                                                                                                             
   TX            ---                 ---                        ---                        7                          ---                         9                        14                              30
   T1            ---                 ---                        54                         26                         7                           ---                      4                               91
   T2a           ---                 ---                        ---                        24                         9                           ---                      7                               41
   T2b           ---                 ---                        ---                        12                         3                           ---                      3                               18
   T2c           ---                 ---                        ---                        15                         2                           ---                      ---                             17
   T3a           ---                 ---                        ---                        ---                        32                          ---                      4                               36
   T3b           ---                 ---                        ---                        ---                        7                           ---                      5                               12
   T4            ---                 ---                        ---                        ---                        1                           ---                      ---                             1
                                                                                                                                                                                                            
  *M-category*                                                                                                                                                                                             
   M0            ---                 ---                        54                         84                         61                          9                        3                               211
   M1a           ---                 ---                        ---                        ---                        ---                         ---                      ---                              
   M1b           ---                 ---                        ---                        ---                        ---                         ---                      15                              15
   M1c           ---                 ---                        ---                        ---                        ---                         ---                      19                              19

Abbreviations: CRPC-MET=castrate-resistant, metastatic prostate cancer; LR=local recurrence; PSA=prostate-specific antigen.
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